High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS ... of revumenib (drug used in hematologic malignancies). Positive controls involved cell lines treated with staurosporine ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia ... while active negative control varying concentrations of revumenib (drug used in ...